|Bid||0.00 x 1300|
|Ask||0.00 x 1000|
|Day's range||146.41 - 156.31|
|52-week range||89.00 - 383.77|
|Beta (5Y monthly)||1.37|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Feb 2020|
|1y target est||N/A|
Commercial aerospace stocks have taken it on the chin this year as the coronavirus pandemic has wiped out demand for air travel and caused the airlines to scramble to cut costs. Shares of Boeing (NYSE: BA) have lost more than half their value year to date, likely tempting bargain hunters to buy in and wait for the eventual rebound in aviation demand. Here's why I believe TransDigm Group (NYSE: TDG) is a better choice for investors interested in commercial aerospace right now.
Right now, there are 50 coronavirus vaccine candidates in clinical trials worldwide, and there is a good chance that at least one of them can earn approval from the U.S. Food and Drug Administration (FDA). If that happens, any business that had its revenues hit hard by COVID-19 could witness a full-on recovery and major gains in its stock price. This could happen sooner than we think; Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are set to publish results on large-scale testing of their experimental coronavirus vaccine next month, and 10 other candidates are in phase 3 clinical trials.
The buying has to be strong enough to break the lower-top, lower-bottom chart pattern in order to create enough upside momentum to change the trend.